

William MacNee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4163547/publications.pdf>

Version: 2024-02-01

37
papers

2,359
citations

236612

25
h-index

329751

37
g-index

38
all docs

38
docs citations

38
times ranked

3644
citing authors

#	ARTICLE	IF	CITATIONS
1	Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 382-386.	2.5	257
2	Title is missing!. Molecular and Cellular Biochemistry, 2002, 234/235, 239-248.	1.4	218
3	Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. Journal of the American Medical Directors Association, 2012, 13, 291-297.	1.2	193
4	Oxidants and Antioxidants as Therapeutic Targets in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 1999, 160, S58-S65.	2.5	185
5	Lessons from ECLIPSE: a review of COPD biomarkers. Thorax, 2014, 69, 666-672.	2.7	125
6	Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax, 2013, 68, 738-745.	2.7	120
7	Pathogenesis of Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2007, 28, 479-513.	0.8	106
8	New Paradigms in the Pathogenesis of Chronic Obstructive Pulmonary Disease I. Proceedings of the American Thoracic Society, 2009, 6, 527-531.	3.5	101
9	Accelerated lung aging: a novel pathogenic mechanism of chronic obstructive pulmonary disease (COPD). Biochemical Society Transactions, 2009, 37, 819-823.	1.6	95
10	Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. Respiratory Medicine, 2015, 109, 1138-1146.	1.3	77
11	Genome-wide mRNA expression profiling in vastus lateralis of COPD patients with low and normal fat free mass index and healthy controls. Respiratory Research, 2015, 16, 1.	1.4	73
12	Characterisation of $\hat{1}^3$ -glutamylcysteine synthetase-heavy subunit promoter: a critical role for AP-1. FEBS Letters, 1998, 427, 129-133.	1.3	72
13	Apocynin increases glutathione synthesis and activates AP-1 in alveolar epithelial cells. FEBS Letters, 1999, 443, 235-239.	1.3	71
14	Oxidants and COPD. Inflammation and Allergy: Drug Targets, 2005, 4, 627-641.	3.1	71
15	Diagnosis, assessment, and phenotyping of COPD: beyond FEV1. International Journal of COPD, 2016, 11 Spec Iss, 3.	0.9	63
16	Quantification of Lung PET Images: Challenges and Opportunities. Journal of Nuclear Medicine, 2017, 58, 201-207.	2.8	55
17	One-year change in health status and subsequent outcomes in COPD. Thorax, 2015, 70, 420-425.	2.7	50
18	A review of the most common patient-reported outcomes in COPD – revisiting current knowledge and estimating future challenges. International Journal of COPD, 2015, 10, 725.	0.9	48

#	ARTICLE	IF	CITATIONS
19	Evaluation of exhaled breath condensate pH as a biomarker for COPD. <i>Respiratory Medicine</i> , 2011, 105, 1037-1045.	1.3	45
20	Low sputum MMP-9/TIMP ratio is associated with airway narrowing in smokers with asthma. <i>European Respiratory Journal</i> , 2014, 44, 895-904.	3.1	33
21	Ectopic fat accumulation in patients with COPD: an ECLIPSE substudy. <i>International Journal of COPD</i> , 2017, Volume 12, 451-460.	0.9	33
22	Regulation of iNOS expression and glutathione levels in rat liver by oxygen tension. <i>FEBS Letters</i> , 2000, 476, 253-257.	1.3	30
23	Combination of erythromycin and dexamethasone improves corticosteroid sensitivity induced by CSE through inhibiting PI3K- \hat{I} /Akt pathway and increasing GR expression. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 309, L139-L146.	1.3	30
24	Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , 2016, 119, 87-95.	1.3	29
25	Right Heart Function in COPD. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 295-312.	0.8	27
26	Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2016, 48, 1215-1218.	3.1	25
27	Exploring the concept of need in people with very severe chronic obstructive pulmonary disease: a qualitative study. <i>BMJ Supportive and Palliative Care</i> , 2018, 8, 468-474.	0.8	22
28	Role of accelerated aging in limb muscle wasting of patients with COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 1987-1998.	0.9	16
29	Update in Chronic Obstructive Pulmonary Disease 2007. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 820-829.	2.5	14
30	Risk assessment for hospital admission in patients with COPD; a multi-centre UK prospective observational study. <i>PLoS ONE</i> , 2020, 15, e0228940.	1.1	13
31	Short physical performance battery as a practical tool to assess mortality risk in chronic obstructive pulmonary disease. <i>Age and Ageing</i> , 2021, 50, 795-801.	0.7	12
32	Dynamic (4D) CT perfusion offers simultaneous functional and anatomical insights into pulmonary embolism resolution. <i>European Journal of Radiology</i> , 2016, 85, 1883-1890.	1.2	11
33	Short Physical Performance Battery: What Does Each Sub-Test Measure in Patients with Chronic Obstructive Pulmonary Disease?. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 7, 13-25.	0.5	10
34	2D-DIGE proteomic analysis of vastus lateralis from COPD patients with low and normal fat free mass index and healthy controls. <i>Respiratory Research</i> , 2017, 18, 81.	1.4	9
35	Consensus Recommendations on the Use of 18F-FDG PET/CT in Lung Disease. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1701-1707.	2.8	8
36	Computed tomography-derived pathological phenotypes in COPD. <i>European Respiratory Journal</i> , 2016, 48, 10-13.	3.1	7

#	ARTICLE	IF	CITATIONS
37	Nitric oxide production, alveolar macrophages and type II alveolar epithelial cells in response to LPS in vivo and in vitro. <i>Biochemical Society Transactions</i> , 1995, 23, 233S-233S.	1.6	5